Sign up
Pharma Capital

Progenics Pharmaceuticals shares plummet after failed Phase 3 prostate cancer trial

The company’s imaging agent was unable to meet the study’s target for detecting prostate cancer
Scientist sitting at a microscope
Progenics Pharmaceuticals develops imaging analysis technology to detect and treat cancer

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) shares dropped double digits after announcing its Phase 3 clinical trial for its prostate cancer imaging agent had failed.

Shares of Progencs were halted Wednesday in after-hours trading before falling sharply following the announcement.

READ: Shares of Foamix Pharmaceuticals Ltd soar after its acne drug meets main goals in late-stage trial

Its shares continued falling in Thursday pre-market trading, dropping more than 18% to US$5.97.

The clinical trial found that its 1404 imaging agent was supposed to be able to detect prostate cancer with a 60% or higher sensitivity but fell in the range of 47% to 51%.

"These top line Phase 3 results of 1404 are inconsistent with the prior Phase 2 data, which showed significantly higher sensitivity rates," said CEO Mark Baker in the company’s press release.

The imaging agent was able to detect the absence of prostate cancer ahead of the study’s target, having a specificity of 71% to 75% compared with the 60% target.

The New York-based oncology company develops medicines and imaging analysis technology to detect and treat cancer.


Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.